Elevance Health enters the second half of 2026 confronting a confluence of pressures that is producing the worst reported earnings results the company has posted in years. Second quarter shareholders' net income of $1,463M was down 16.1% from a year earlier, and diluted EPS of $6.71 was off 13.1% despite a $1.36B share repurchase that shrunk the diluted share count by 3.5%. The drop is not a function of weak demand for the underlying business. Total operating revenue still grew, the benefit expense ratio remains comfortably inside the company's own 90.2% full-year guidance, and net investment income rose 44.9% on stronger alternative-investment returns. The problem is concentrated on the cost side: a higher medical loss ratio, an 80 basis point lift in the operating expense ratio, and a one-time loss contingency accrual tied to the historical Medicare Advantage risk adjustment matter that the company disclosed in the first quarter.
What changed during the second quarter is that the worst-case scenarios in the management's regulatory and medical-cost playbook have started to materialize simultaneously. The One Big Beautiful Bill Act has set in motion Medicaid eligibility re-verifications and provider tax changes that will bite hardest in 2027 and 2028, but already have visible effects on membership and pricing. The expiration of the enhanced Premium Tax Credits at the end of 2025 has reshaped the Individual ACA market, and the company is deliberately repositioning its Medicare Advantage footprint away from geographies and products that do not meet internal return thresholds. Star Ratings improved, with 59% of Medicare Advantage members in plans rated 4.0 stars or higher for 2026, which should support 2027 bonus payments, but the in-year operating gain still fell.
The strongest evidence supporting a constructive view is the underlying cash generation. Operating cash flow doubled to $6,245M in the first half, the company closed the CMS enforcement action on the historical risk adjustment matter with no sanctions imposed, and full-year 2026 adjusted EPS guidance of at least $26.75 is unchanged from the reaffirmation on June 10, 2026. The strongest counterargument is that GAAP EPS of at least $19.85 incorporates roughly $6.90 of net unfavorable items, and second half normalization is required to actually hit that floor. The most important forward variable is the benefit expense ratio trajectory into the back half; if elevated medical cost trend persists, the 90.2% full-year target becomes difficult to defend. At approximately $403 per share, the stock trades at about 20.3x the 2026 GAAP EPS floor and roughly 15.1x the adjusted figure, which is a meaningful discount to the multiple the company commanded in 2024 but no longer obviously cheap relative to peers facing the same headwinds.